Each ml of product contains:
Testosterone Enanthate 250 mg.
Testosterone enanthate, a derivative of the primary endogenous androgen testosterone, for intramuscular administration.
Testosterone Enanthate is indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism: Testicular failure due to cryptorchisdism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectorny. Hypogonadotropic hypogonadism: Idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary- hypothalamic injury from tumors, trauma, or radiation. Delayed puberty: Testosterone Enanthate may be used to stimulate puberty in carefully selected males with clearly delayed puberty.
INDICATI ON FEMALES
Metastatic mammary cancer: Testosterone Enanthate may be used secondarily in women with advancing inoperable metastatic mammary cancer who are one to five years postmenopausal. It has also been used in premenopausal women with breast cancer who have benefited from ophorectomy and are considered to have a hormone-responsive tumor.
When administered concurrently, the following drugs may interact with androgens, such as Methandrostenolone, have been reported to decrease the anticoagulant requirement. Patients receiving oral anticoagulant therapy require close monitoring especially when androgens are started or stopped.
Androgens are contraindicated in men with carcinomas of the breast or with known or suspected carcinomas of the prostate and in women who are or may become pregnant. When administered to pregnant women, androgens cause virility of the external genitalia of the female fetus. This virility includes clitoromegaly, abnormal vaginal development and fusion of genital folds to form a scrotal-like structure. This preparation is also contraindicated in patients with a history of hypersensitivity to any of its components.
Generally, women should be observed for signs of virility. Because androgens may alter serum cholesterol concentration, caution should be used when administering these drugs to patients with a history of myocardial infarction or coronary disease. All patients: Any nausea, vomiting, changes in skin or ankle swelling.
DOSAGE AND ADMINISTRATION
In males with delayed puberty: Various dosage regimens have been used; some call for lower dosages initially with gradual increases as puberty progresses, with or without a decrease to maintenance levels. Other regimens call for higher losage to induce pubertal changes and lower dosage for maintenance after puberty. The chronological and skeletal ages must be taken into consideration, both in determining the initial dose and in adjusting the dose. Dosage is within the range of 50 to 200 mg every 2 to 4 weeks for a limited duration, for example, 4 to 6 months.
Store in a cool dry place. Protect from light.